title: Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy.
abstract: Amifostine is an organic thiophosphate prodrug used for cytoprotection against toxic effects of radiotherapy and chemotherapy. In a European prospective study of SJS/TEN, six patients were suspected to have SJS/TEN associated with amifostine. Our findings suggest that the risk of life-threatening cutaneous adverse reactions to amifostine could be significantly increased.
authors.affiliation: Department of Dermatology, Université Paris XII, Créteil Cedex, France. laurence.allanore@hmn.aphp.fr
authors.forename: Laurence
authors.initials: L
authors.lastname: Valeyrie-Allanore
authors.forename: Nicolas
authors.initials: N
authors.lastname: Poulalhon
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Fagot
authors.forename: Peggy
authors.initials: P
authors.lastname: Sekula
authors.forename: Batya
authors.initials: B
authors.lastname: Davidovici
authors.forename: Alexis
authors.initials: A
authors.lastname: Sidoroff
authors.forename: Maja
authors.initials: M
authors.lastname: Mockenhaupt
mesh_terms: D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D004999:Amifostine / Q000009:adverse effects*; D005060:Europe; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011837:Radiation-Protective Agents / Q000009:adverse effects*; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000209:etiology*
chemical_list: D011837:Radiation-Protective Agents; D004999:Amifostine